These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36400479)

  • 1. French AFU Cancer Committee Guidelines - Update 2022-2024: Non-muscle-invasive bladder cancer (NMIBC).
    Neuzillet Y; Pradère B; Xylinas E; Allory Y; Audenet F; Loriot Y; Masson-Lecomte A; Roumiguié M; Seisen T; Traxer O; Leon P; Roupret M
    Prog Urol; 2022 Nov; 32(15):1102-1140. PubMed ID: 36400479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [CCAFU Recommendations 2013: Bladder carcinoma].
    Pfister C; Roupret M; Neuzillet Y; Larré S; Pignot G; Quintens H; Houedé N; Compérat E; Colin P; Roy C; Davin JL; Guy L; Irani J; Lebret T; Coloby P; Soulié M;
    Prog Urol; 2013 Nov; 23 Suppl 2():S105-25. PubMed ID: 24485286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [French ccAFU guidelines - update 2020-2022: bladder cancer].
    Rouprêt M; Pignot G; Masson-Lecomte A; Compérat E; Audenet F; Roumiguié M; Houédé N; Larré S; Brunelle S; Xylinas E; Neuzillet Y; Méjean A
    Prog Urol; 2020 Nov; 30(12S):S78-S135. PubMed ID: 33349431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [CCAFU french national guidelines 2016-2018 on bladder cancer].
    Rouprêt M; Neuzillet Y; Masson-Lecomte A; Colin P; Compérat E; Dubosq F; Houédé N; Larré S; Pignot G; Puech P; Roumiguié M; Xylinas E; Méjean A
    Prog Urol; 2016 Nov; 27 Suppl 1():S67-S91. PubMed ID: 27846935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
    Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
    Babjuk M; Burger M; Zigeuner R; Shariat SF; van Rhijn BW; Compérat E; Sylvester RJ; Kaasinen E; Böhle A; Palou Redorta J; Rouprêt M;
    Eur Urol; 2013 Oct; 64(4):639-53. PubMed ID: 23827737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).
    Babjuk M; Burger M; Capoun O; Cohen D; Compérat EM; Dominguez Escrig JL; Gontero P; Liedberg F; Masson-Lecomte A; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Seisen T; Soukup V; Sylvester RJ
    Eur Urol; 2022 Jan; 81(1):75-94. PubMed ID: 34511303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
    Babjuk M; Burger M; Compérat EM; Gontero P; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Zigeuner R; Capoun O; Cohen D; Escrig JLD; Hernández V; Peyronnet B; Seisen T; Soukup V
    Eur Urol; 2019 Nov; 76(5):639-657. PubMed ID: 31443960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. French AFU Cancer Committee Guidelines - Update 2022-2024: Muscle-Invasive Bladder Cancer (MIBC).
    Neuzillet Y; Audenet F; Loriot Y; Allory Y; Masson-Lecomte A; Leon P; Pradère B; Seisen T; Traxer O; Xylinas E; Roumiguié M; Roupret M
    Prog Urol; 2022 Nov; 32(15):1141-1163. PubMed ID: 36400480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [French ccAFU guidelines – Update 2018–2020: Bladder cancer].
    Rouprêt M; Neuzillet Y; Pignot G; Compérat E; Audenet F; Houédé N; Larré S; Masson-Lecomte A; Colin P; Brunelle S; Xylinas E; Roumiguié M; Méjean A
    Prog Urol; 2019 Sep; 28(S1):R48-R80. PubMed ID: 32093463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update.
    Babjuk M; Oosterlinck W; Sylvester R; Kaasinen E; Böhle A; Palou-Redorta J; Rouprêt M;
    Eur Urol; 2011 Jun; 59(6):997-1008. PubMed ID: 21458150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M; Olaru V
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Guidelines from the cancer committee of the French Association of Urology (CC-AFU) for adequate intravesical instillations of Mitomycin C, Epirubicin, and BCG for non-muscle invasive bladder cancer].
    Leon P; Saint F; Audenet F; Roumiguié M; Allory Y; Loriot Y; Masson-Lecomte A; Pradère B; Seisen T; Traxer O; Xylinas E; Roupret M; Neuzillet Y
    Prog Urol; 2022 Apr; 32(5):299-311. PubMed ID: 35151545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer.
    Monteiro LL; Witjes JA; Agarwal PK; Anderson CB; Bivalacqua TJ; Bochner BH; Boormans JL; Chang SS; Domínguez-Escrig JL; McKiernan JM; Dinney C; Godoy G; Kulkarni GS; Mariappan P; O'Donnell MA; Rentsch CA; Shah JB; Solsona E; Svatek RS; van der Heijden AG; van Valenberg FJP; Kassouf W
    World J Urol; 2019 Jan; 37(1):51-60. PubMed ID: 30109483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intravesical adjuvant regimen of epitubicin for intermediate risk NMIBC: Feasability study from CC-AFU vessie].
    Rollin P; Xylinas E; Lanz C; Audenet F; Brunelle S; Compérat E; Houédé N; Larré S; Masson-Lecomte A; Pignot G; Roumiguié M; Méjean A; Rouprêt M; Neuzillet Y;
    Prog Urol; 2022 Apr; 32(5):326-331. PubMed ID: 35151544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnosis of and therapy for non-muscle-invasive bladder cancer - state of the art].
    Kausch von Schmeling I
    Aktuelle Urol; 2010 Sep; 41(5):307-15. PubMed ID: 20824576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
    Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
    J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
    Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
    BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective descriptive 1-year study in France of all BCG therapy dispensations for non-muscle-invasive bladder cancer.
    Neuzillet Y; Leon P; Seisen T; Allory Y; Audenet F; Loriot Y; Masson-Lecomte A; Mejean A; Pradère B; Roumiguié M; Traxer O; Xylinas E; Fournier G; Roupret M
    BJU Int; 2023 May; 131(5):611-616. PubMed ID: 36462164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.